European Study of Quality of Life in Resistant OCD Patients Treated by STN DBS (EQOLOC)

  • STATUS
    Recruiting
  • End date
    Dec 20, 2026
  • participants needed
    60
  • sponsor
    University Hospital, Grenoble
Updated on 20 April 2022
psychiatric disorder
antipsychotics
lithium
exposure therapy
psychotherapy
brain stimulation
clomipramine

Summary

Obsessive-Compulsive Disorder (OCD) is among the most disabling psychiatric disorders as more than 40% of patients are resistant to the standard pharmacological and psychotherapy approaches and about 10% show severe disability and require institutionalization. These resistant patients may benefit from new surgical therapeutic approaches such as Deep Brain Stimulation (DBS) using high frequency stimulation of specific cerebral regions to modulate neural networks. Although promising, these results need nevertheless to be replicated and confirmed within a larger cohort of patients and considering a different main objective, instead of clinical improvement only. Indeed, despite a positive treatment response, adaptive functioning and quality of life may continue to be negatively impacted in OCD. Thus beyond symptom reduction, health-related quality of life (QoL) represents a more important objective of a treatment, as it includes both the individual's functional status and the individual's subjective perception of the impact of the illness on the patient's life. STN DBS induces significant clinical improvement, which may not be proportional to the QoL gain. Consequently, QoL appears to be a better outcome to target in the coming studies than clinical improvement alone. THe investigators thus propose a prospective study assessing the QoL changes of resistant OCD patients under STN DBS+BMT versus Best Medical Treatment (BMT) at 12 months, in order to assess the DBS induced gain in QoL in BMT-managed patients versus BMT alone.

Description

The study will focus on an innovative therapeutic strategy (DBS) and on an original objective, quality of life, which is considered to better reflect the impact of a therapeutic strategy. Moreover, the study will help to define the predictive biomarkers /biosignatures of response to STN DBS in OCD.

Details
Condition Obsessive-Compulsive Disorder
Treatment Deep brain stimulation
Clinical Study IdentifierNCT02844049
SponsorUniversity Hospital, Grenoble
Last Modified on20 April 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

OCD for > 5 years
YBOCS> 25 and/or YBOCS sub-scale >15
GAF< 45
or more documented SRI trials, including clomipramine (10-12 weeks at adequate dose)
SRI augmentation for > 4 weeks with at least one antipsychotic and with one of the following: lithium, clonazepam
Adequate trial of CBT (Exposure Therapy and Response Prevention) (intolerance or >15 sessions)
Ability to provide informed consent

Exclusion Criteria

Hoarding (if the only OCD symptom)
OCD with poor insight (BABS score > 12)
Lifetime diagnosis of psychosis or bipolar disorder
Substance abuse or dependence within the previous six months
Baseline Montgomery and Asberg (MADRS) suicidality item (item 10) score >2
Current DSM-5 personality disorder of Cluster A (e.g., paranoid or schizotypal personality disorder) or B (e.g., borderline or antisocial personality disorder)
Brain pathology, such as moderate or marked cerebral atrophy, stroke, tumor or previous neurosurgical procedures (i.e. capsulotomy etc), history of cognitive impairment and cognitive deterioration (Addenbrooke's Cognitive Examination ACE score of < 80)
Contra-indications to surgery, anaesthesia, or MRI
compulsory hospitalization/ care; pregnant or nursing patients
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note